Key market players, such as Novo Nordisk A/S, Eli Lilly, and Pfizer, are focusing on technological advancements to enhance the safety and convenience of GLP-1 therapies in diabetes care and weight management
The SURMOUNT-5 trial showed 20.2% vs 13.7% weight loss, and Second Natures real-world data showed 22.1% vs 17.1%
NexLife scores 94/100 six of six v3.0 pillars (documented clinical protocol, named compounding pharmacies, published cohort outcomes, flat dose-independent pricing, included labs, full regulatory clarity)
Aporta mucha energa Frequently Asked Questions Dont stay in doubt
However, we have tried to make a more equitable comparison by choosing similar timepoints across all drugs (when available) and summarise them below